Patriot One Technologies Inc., - CEO, Martin Cronin
CEO, Martin Cronin
Source: Blue Line
  • Patriot One Technologies (PAT) subsidiary, Xtract Technologies, has revealed a new project contract with Canexia Health
  • The project aims to increase access to cancer testing for patients impacted by delays related to the COVID-19 pandemic
  • In Canada, at least 100,000 surgeries, including cancer tissue biopsies, have been delayed or postponed due to COVID-19
  • The project plans to provide a liquid biopsy solution, which will serve as a minimally invasive alternative to surgical tissue biopsies
  • Patriot One (PAT) is up 2.94 per cent and is currently trading at C$1.05 per share

Patriot One Technologies (PAT) subsidiary, Xtract Technologies, has revealed a new project contract with Canexia Health.

The contract is for Project ACTT (Access to Cancer Testing & Treatment in Response to COVID-19). The project is part of, and supported by, the Digital Technology Supercluster COVID-19 program. 

Project ACTT’s aim is to increase access to cancer testing for patients impacted by delays related to the COVID-19 pandemic. Since the coronavirus outbreak began, other medical conditions have had to take a necessary backseat to the more pressing pandemic. 

Hospitals all over the world have been overwhelmed by COVID-19 cases, which have taken priority over other conditions. Enforced lockdowns have also reduced the number of people visiting hospitals for medical care.

In addition, some people have actively avoided going to hospital, in order to reduce their possible exposure to the virus. Many groups of people are particularly vulnerable to COVID-19, due to old age, or pre-existing medical conditions, like diabetes or autoimmune diseases.

Cancer patients are twice as likely to contract COVID-19, and three times as likely to die from it, when compared to the general population. Unfortunately, by delaying treatments for the sick, COVID-19 has also given other diseases the chance to worsen or spread further. 

In Canada, at least 100,000 surgeries have been delayed or postponed since early March, due to COVID-19. Some of these delayed surgeries would include cancer tissue biopsies.

Project ACTT intends to provide a liquid biopsy solution, which will serve as a non-invasive alternative to surgical tissue biopsies. The solution will involve a simple blood draw, which artificial intelligence technology will analyse for circulating tumour DNA. 

Patriot One’s Xtract Technologies will develop, train, and deploy Natural Language Processing (NLP) models for the project. The NLP models will help to manage, understand, and integrate semi-structured information from a mutation and cancer-type database.

Patriot One’s CEO, Martin Cronin, commented on the company’s involvement in Project ACTT.

“Knowing how far-reaching the effects of COVID-19 are, we’re delighted to be involved in another project utilising artificial intelligence, and our team’s expertise, in an effort to significantly, and hopefully positively, impact the lives of cancer patients,” he said.

Patriot One (PAT) is up 2.94 per cent and is trading at C$1.05 per share at 11:58am EDT.

More From The Market Online

Stantec tapped to design Tata Group’s new battery plant

Stantec has won a contract with Agratas, Tata Group’s battery business, to design a £4 billion (C$6.86B) battery cell facility in the U.K.

Buzz on the Bullboards: Hot stocks from copper to Bombardier and AI

Not only is it an extra day to hold off on rent/mortgage payments, but an extra day to take stock of February's wild ride.

Liberty Defense receives US$1M from Viken Detection

Liberty Defense (TSXV:SCAN) has received US$1 million in funding from Viken Detection for further production of HEXWAVE and other purposes.

Reliq Health Technologies expands mental health offering

Reliq Health Technologies (TSXV:RHT) will now provide cognitive assessments as part of its mental health services to improve early detection.